ADHD Medication Denied by Insurance
Why would insurance deny ADHD medication?
A plan can deny an ADHD medicine because an approval was missing, because its policy requires another drug first, because of a quantity limit, because the drug is not on the formulary, or because it says the prescription is not medically necessary. A generic, including generic Adderall, can be denied for any of those reasons. The notice states which one it used. FDA's Orange Book lists drug products FDA has approved. A listing is not a decision that your plan covers the drug. This page explains the denial and the appeal. It does not promise coverage.
Get help with my bill →What should I read on an ADHD medication denial?
The Adderall XR label points below were checked on the FDA prescribing information on November 17, 2026. The denial notice controls the drug name, the reason, and the deadline.
Read the notice for the drug name, the strength, the quantity, and the reason. A missing approval, step therapy, a quantity limit, a formulary exclusion, and a medical-necessity decision are different problems. HealthCare.gov defines a formulary as the plan's drug list. HealthCare.gov says prior authorization is a decision about whether a service is medically necessary, and that it is not a promise of payment. If the notice says approval was missing, see a prior authorization denial. If another drug had to be tried first, see a step therapy denial. If the drug is not on the list, see a prescription drug the plan will not cover. If the notice says the drug is not medically necessary, see a medical necessity denial.
The FDA label for Adderall XR, mixed salts of a single-entity amphetamine product, says it is indicated for the treatment of attention deficit hyperactivity disorder in adults and in pediatric patients 6 years and older. The label says use is not recommended in pediatric patients younger than 6 years of age. Immediate-release Adderall is a different product. Other ADHD medicines have their own labels. Use the name on your denial. Do not change or stop a medicine on your own. Ask the prescriber what to do if you may run out.
References: HealthCare.gov: Preauthorization · HealthCare.gov: Formulary · FDA: Adderall XR prescribing information · HealthCare.gov: Internal appeals
What if insurance will not cover generic Adderall?
A plan can leave a generic off the formulary, cover one manufacturer's product and not another, or apply prior authorization, step therapy, or a quantity limit to the generic. Those are different denials. Ask the notice which one it used. FDA's Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations, identifies drug products approved on the basis of safety and effectiveness. A listing there is not a coverage decision. Do not assume a generic is covered because a brand is covered, and do not assume the brand is covered because a generic is not.
When a health plan provides essential health benefits, 45 CFR 156.122(c) is a process for you, your designee, or your prescriber to request a clinically appropriate drug the plan does not otherwise cover. HealthCare.gov describes prescription drugs as one of the essential health benefit categories. A plan that does not provide those benefits may not use this section. Ask the plan whether it does. For a standard exception, the plan must decide no later than 72 hours after it receives the request. For an expedited request, when exigent circumstances exist, it must decide no later than 24 hours. Those hours are the plan's time to decide. They are not your deadline to file. The rest of that process is in a prescription drug the plan will not cover.
References: FDA: Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations · HealthCare.gov: Formulary · 45 CFR 156.122: Essential health benefit prescription drug exceptions · HealthCare.gov: Essential health benefits, including pediatric dental
What if the plan limits the quantity or requires another drug first?
A quantity limit and a step-therapy rule are the plan's written policy unless a Medicare rule on the notice applies. Ask for the policy. Your prescriber can respond to the limit or the step the policy actually states. Do not ask anyone to record a trial that did not happen, and do not ask the pharmacy to dispense more than the prescription allows.
For Medicare Part D, 42 CFR 423.153(b) requires the plan to have a drug utilization management program, including policies and systems to help prevent over-utilization and under-utilization. CMS's Prescription Drug Benefit Manual, Chapter 6, section 30.2.2.1, revision issued January 15, 2016, says the plan must submit point-of-sale prior authorization, step therapy, and quantity limits that are not based on the FDA maximum daily dose as part of the formulary submission. A quantity limit that allows dispensing up to the FDA-approved maximum daily dose does not have to be submitted. A quantity limit below that maximum, or below the days' supply in the plan benefit package, must be included for CMS review. 42 CFR 423.578(b) says formulary use includes a dose restriction that causes a Part D drug not to be covered for the number of doses prescribed, a step therapy requirement, and a therapeutic substitution requirement. The plan must grant an exception when it determines the drug is medically necessary, consistent with the prescriber's statement, and the drug would be covered but for that formulary rule. 42 CFR 423.578(f) says the prescriber's supporting statement does not, by itself, produce an approval.
References: 42 CFR 423.153: Part D drug utilization management · CMS Medicare Prescription Drug Benefit Manual, Chapter 6, section 30.2.2, formulary tools including quantity limits · 42 CFR 423.578: Medicare Part D exceptions process · CMS: Medicare Part D exceptions, including step therapy
When is an ADHD drug denial a parity question?
45 CFR 146.136 lists prior authorization, formulary design for prescription drugs, and step therapy, which it also calls fail-first policies, among nonquantitative treatment limitations. Those limits can be a parity question when the plan covers the ADHD drug as a mental health benefit. This page does not decide that your plan classified the drug that way. Ask the plan. Which plans the federal parity law reaches, and where to complain, is in a denied mental health claim. A parity question does not replace the appeal. File the appeal so the deadline on the notice does not pass.
How does Medicare Part D handle an ADHD drug denial?
When an oral ADHD medicine meets the Part D drug definition in 42 CFR 423.100, 42 CFR 423.566 says a decision not to provide or pay for that Part D drug, including because the drug is not on the formulary or is not medically necessary, is a coverage determination. You, your representative, or the prescriber may request it.
42 CFR 423.568 says that for a request for a drug benefit, the plan must notify you as expeditiously as your health requires and no later than 72 hours after it receives the request. For an exceptions request, that 72 hours runs from receipt of the prescriber's supporting statement. If the statement is not received by the end of 14 calendar days, the plan decides no later than 72 hours after those 14 days end. 42 CFR 423.570 says an expedited request does not include a request for payment of a Part D drug already furnished. If the plan grants an expedited request, 42 CFR 423.572 says it must decide as expeditiously as your health requires and no later than 24 hours after it receives the request, or after it receives the prescriber's supporting statement when the request is an exception. The redetermination deadline is the date on your notice. The steps are in a prescription drug the plan will not cover.
References: 42 CFR 423.100: Part D drug definition · 42 CFR 423.566: Medicare Part D coverage determinations · 42 CFR 423.568: Medicare Part D coverage determination timeframes · 42 CFR 423.570: Expedited Medicare Part D coverage determinations · 42 CFR 423.572: Timeframes for expedited Medicare Part D coverage determinations · 42 CFR 423.578: Medicare Part D exceptions process
How do I appeal an ADHD medication denial?
Follow the notice. Ask the prescriber for a statement that answers the reason on the denial, and attach the records that show the diagnosis and any drug that was tried or could not be used. For a job-based plan, 29 CFR 2560.503-1 gives at least 180 days to appeal, and 45 CFR 147.136 applies that internal-appeal standard to non-grandfathered coverage. HealthCare.gov explains that appeal. See how to appeal a health insurance denial. If the dispute is whether the drug is medically necessary, the notice may also offer external review. See how to request an external review.
For a private-sector workplace health plan, the Department of Labor says an urgent appeal must be decided as soon as your medical needs require, and no later than 72 hours after the plan receives the appeal. Running out of a medicine is not automatically that urgent appeal. Ask the prescriber whether waiting meets the test, and use the process on the notice. A clinician's call does not move the written deadline unless the notice says it does. Nothing on this page promises that the plan or Medicare will cover the drug.
References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review · U.S. Department of Labor: Filing a claim for your health benefits
What this page cannot promise
This is general information, not medical or legal advice. A plan can leave a generic off the formulary. A quantity limit can stay in place. An exception can be denied. Parity rules apply only when the plan's classification and plan type make them apply. An appeal can leave the denial in place. Nothing on this page promises that a plan or Medicare will cover an ADHD medicine, including generic Adderall, or cancel a bill.
Sources and further help
These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.
- HealthCare.gov: Preauthorization ↗
- HealthCare.gov: Formulary ↗
- HealthCare.gov: Internal appeals ↗
- HealthCare.gov: External review ↗
- U.S. Department of Labor: Filing a claim for your health benefits ↗
- 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period ↗
- 45 CFR 147.136: Internal claims, appeals, and external review ↗
- FDA: Adderall XR prescribing information ↗
- FDA: Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations ↗
- 45 CFR 156.122: Essential health benefit prescription drug exceptions ↗
- HealthCare.gov: Essential health benefits, including pediatric dental ↗
- 42 CFR 423.100: Part D drug definition ↗
- 42 CFR 423.153: Part D drug utilization management ↗
- CMS Medicare Prescription Drug Benefit Manual, Chapter 6, section 30.2.2, formulary tools including quantity limits ↗
- 42 CFR 423.566: Medicare Part D coverage determinations ↗
- 42 CFR 423.568: Medicare Part D coverage determination timeframes ↗
- 42 CFR 423.570: Expedited Medicare Part D coverage determinations ↗
- 42 CFR 423.572: Timeframes for expedited Medicare Part D coverage determinations ↗
- 42 CFR 423.578: Medicare Part D exceptions process ↗
- CMS: Medicare Part D exceptions, including step therapy ↗
- 45 CFR 146.136: Parity in mental health and substance use disorder benefits, including nonquantitative treatment limitations ↗
Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.